Alterity Therapeutics (ATHE) Cash from Operations (2009 - 2020)

Alterity Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 6181351.89 for Q2 2020.

• On a quarterly basis, Cash from Operations rose 36.76% year-over-year to 6181351.89 in Q2 2020; TTM through Jun 2020 was 19370713.16, a 21.79% decrease from a year earlier, with the FY2025 full-year figure at 7333759.44, up 11.72% from the prior year.
• Cash from Operations eased to 6181351.89 in Q2 2020 per ATHE's latest filing, from 1766470.98 in the prior quarter.
• Across five years, Cash from Operations topped out at 1766470.98 in Q4 2019 and bottomed at 9774963.11 in Q2 2019.
• The 5-year median for Cash from Operations is 4405908.68 (2017), against an average of 3414551.96.
• Biggest YoY gain for Cash from Operations was 134.1% in 2019; the steepest drop was 20575.33% in 2019.
• Year by year, Cash from Operations stood at 465813.11 in 2016, then tumbled by 93.6% to 901823.06 in 2017, then sank by 474.49% to 5180869.14 in 2018, then soared by 134.1% to 1766470.98 in 2019, then slumped by 449.93% to 6181351.89 in 2020.
• Per Business Quant, the three latest ATHE Cash from Operations figures stand at 6181351.89 (Q2 2020), 1766470.98 (Q4 2019), and 9774963.11 (Q2 2019).